Showing results (401-410 of 415) with videos related to
Sort By:
Pageof 42
International Journal of Clinical Oncology|May 16, 2024
2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesisHirotoshi Iihara, Masakazu Abe, Makoto Wada, et al.International Journal of Clinical Oncology|July 21, 2026
Systematic review of antiemetic therapy for low emetogenic chemotherapy: comparing 5-HT3 receptor antagonists and dexamethasoneTakeshi Aoyama, Hirotoshi Iihara, Masakazu Abe, et al.International Journal of Clinical Oncology|November 12, 2024
Efficacy and safety of multi-day antiemetic treatment for patients undergoing multi-day chemotherapy: a systematic review of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical OncologyKazuhisa Nakashima, Saki Harashima, Rena Kaneko, et al.International Journal of Radiation Oncology, Biology, Physics|August 16, 2005
An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomachSung Kim, Do Hoon Lim, Jeeyun Lee, et al.Nature Communications|December 2, 2024
Xenogeneic-free culture of human intestinal stem cells on functional polymer-coated substrates for scalable, clinical-grade stem cell therapySeonghyeon Park, Ohman Kwon, Hana Lee, et al.International Journal of Clinical Oncology|November 21, 2024
Clinical benefits of adding olanzapine to 5-HT3 receptor antagonist, NK1 receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical OncologyMichiyasu Murakami, Yoshiharu Miyata, Kazuhisa Nakashima, et al.International Journal of Clinical Oncology|May 9, 2024
Non-pharmacological treatments for anticipatory nausea and vomiting during chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023Masamitsu Kobayashi, Jun Kako, Arisa Iba, et al.International Journal of Clinical Oncology|September 28, 2024
Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with highly emetogenic risk antineoplastic agents: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical OncologyAyako Yokomizo, Kazuhisa Nakashima, Arisa Iba, et al.International Journal of Clinical Oncology|September 11, 2024
Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncologyToshinobu Hayashi, Shun Yamamoto, Yoshiharu Miyata, et al.International Journal of Clinical Oncology|November 8, 2020
Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for AntiemesisKenjiro Aogi, Hideki Takeuchi, Toshiaki Saeki, et al.Pageof 42